Hi-Tech Pharmacal Co., Inc. (HITK)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Employees:
369 BAYVIEW AVENUE, AMITYVILLE, NY 11701
5167898228

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

N/A

Data derived from most recent annual or quarterly report
Market Cap 590.159 Million Shares Outstanding13.57 Million Avg 30-day Volume 150.16 Thousand
P/E Ratio64.9517 Dividend Yield0.0 EPS1.03
Price to Revenue2.7043 Debt to Equity0.0 EBITDA12.341 Million
Price to Book Value2.2769 Operating Margin19.0881 Enterprise Value528.71 Million
Current Ratio8.106 EPS Growth-0.705 Quick Ratio5.704
1 Yr BETA 0.0207 52-week High/Low 0.0 / Profit Margin4.1635
Operating Cash Flow Growth-23.0396 Altman Z-Score14.6227 Free Cash Flow to Firm 10.898 Million
View SEC Filings from HITK instead.

View recent insider trading info

Hi-Tech Pharmacal Co., Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding HITK (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HITK

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

APRIL GARY M PRESIDENT, HCP DIVISION

  • Officer
 0 2013-12-13 0

SELTZER REUBEN VICE CHAIRMAN, BUSINESS DEV'T

  • Officer
  • Director
 824,068 2013-10-10 0

SELTZER DAVID S CEO, PRESIDENT, SEC'Y, TREAS.

  • Officer
  • Director
  • 10% Owner
 1,564,539 2013-10-08 0

GOLDWYN MARTIN M

  • Director
 0 2013-10-04 0

PETERS WILLIAM J EVP & CHIEF FINANCIAL OFFICER

  • Officer
 0 2013-10-03 0

SIMPSON BRUCE W

  • Director
 0 2013-10-01 0

HIRSHAUT YASHAR

  • Director
 56,750 2013-09-17 0

EGBARIA KAMEL CHIEF SCIENTIFIC OFFICER, EVP

  • Officer
 0 2013-05-22 0

DURRANT CAMERON

  • PRESIDENT, CEO OF ECR PHARM.
 0 2013-03-11 0

PUGLISI ANTHONY J

  • Director
 0 2012-11-07 0

VAN HULST JACK

  • Director
 0 2012-11-07 0

CASKEY DAVIS S OFFICER

  • Officer
 0 2012-07-16 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MANAGEMENT CO /NY

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
 No longer subject to file 2010-12-09 0

HARVEY BRYCE M OFFICER

  • Officer
 0 2010-11-10 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD PARTNERS, LP

DEERFIELD MANAGEMENT CO /NY

DEERFIELD INTERNATIONAL LTD

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
 1,485,244 2010-07-19 0

ACCIPITER CAPITAL MANAGEMENT, LLC

CANDENS CAPITAL LLC

HOFFMAN GABE

ACCIPITER LIFE SCIENCES FUND II L P

ACCIPITER LIFE SCIENCES FUND II OFFSHORE LTD

ACCIPITER LIFE SCIENCES FUND LP

ACCIPITER LIFE SCIENCES FUND OFFSHORE LTD

ACCIPITER LIFE SCIENCES FUND II QP L P

  • 10% Owner
 No longer subject to file 2008-03-11 0

HOLSTER ROBERT M

  • Director
 12,375 2007-11-15 0

BAR GIORA ELAN EXECUTIVE VP - OPERATIONS

  • Officer
 15,000 2006-03-08 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments